Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411053 | 0.93 | SMN1; SMN2 (0.56) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25823048 | 0.87 | ALDH1A1 (0.46) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25884564 | 0.86 | TOP2A (0.47) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21151887 | 0.86 | TOP2A (0.47) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25884924 | 0.86 | TOP2A (0.47) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27346283 | 0.86 | APP (0.46) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL452919 | 0.85 | MEN1 (0.55) | TOP2ATOP2BMEN1KMT2AALDH1A1 | |
| SCHEMBL18430370 | 0.84 | L3MBTL1 (0.45) | MEN1KMT2ASMN1; SMN2L3MBTL1APP | |
| SCHEMBL19513381 | 0.84 | MEN1 (0.58) | TOP2ATOP2BMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25822746 | 0.84 | TPSAB1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024040076-A1 | EXTRACELLULAR VESICLE COMPRISING A BIOLOGICALLY ACTIVE MOLECULE AND A CELL PENETRATNG PEPTIDE CLEAVABLE LINKER | LONZA SALES AG (CH) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024040075-A1 | EXTRACELLULAR VESICLE COMPRISING A BIOLOGICALLY ACTIVE MOLECULE AND A DUAL CLEAVABLE LINKER | LONZA SALES AG (CH) | 2024-02-22 | — | — | WO | disclosed |
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | GENENTECH, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3888691-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020155017-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3218391-B1 | TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2018086139-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067037-A1 | CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE | ADRM1, SSB, FCER2 | TOP2A 1553/4885TOP2B 2191/4885MEN1 4419/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TOP2A 1735/4885TOP2B 1709/4885MEN1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.